Eloxx Pharmaceuticals, Inc. (ELOX) vs INmune Bio, Inc. (INMB)

A side-by-side comparison of Eloxx Pharmaceuticals, Inc. and INmune Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ELOX

Eloxx Pharmaceuticals, Inc.

$52M

$15.09HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT

INMB

INmune Bio, Inc.

$51M

$1.91HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — ELOX vs INMB

growth of $100 · dividends reinvested · last 1y

ELOX +40.0% (+40.0%/yr)INMB +59.0% (+59.0%/yr)INMB compounded faster over this window

ELOX INMB

Metrics side by side

Total return (annualized)

Metric	ELOX	INMB
Total return (1Y)	N/A	-6.70%
Total return CAGR (3Y)	N/A	-34.23%
Total return CAGR (5Y)	N/A	-36.88%

ELOX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full ELOX analysis Full INMB analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.